Ocelot Bio
Company Details
Status: Private
Employees: 11-50
Location:
San Diego, California, United States of America
Type:
sample
Technology:
sample
sample
About: Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Ocelot Bio | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.